Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Business Wire•28/07/2026•16:01 ET
0
Whiz Insights
Get started
Create a free account to read the full story.